HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen
Author(s) -
Joseph G. Jardine,
Daniel W. Kulp,
Colin HavenarDaughton,
Anita Sarkar,
Bryan Briney,
Devin Sok,
Fabian Sesterhenn,
June EreñoOrbea,
Oleksandr Kalyuzhniy,
Isaiah Deresa,
Xiaozhen Hu,
Skye Spencer,
Meaghan Jones,
Erik Georgeson,
Yumiko Adachi,
Michael Kubitz,
Allan C. deCamp,
JeanPhilippe Julien,
Ian A. Wilson,
Dennis R. Burton,
Shane Crotty,
William R. Schief
Publication year - 2016
Publication title -
science
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.aad9195
Subject(s) - immunogen , germline , virology , hiv vaccine , antibody , biology , human immunodeficiency virus (hiv) , immunology , monoclonal antibody , genetics , gene , vaccine trial
Induction of broadly neutralizing antibodies (bnAbs) is a major HIV vaccine goal. Germline-targeting immunogens aim to initiate bnAb induction by activating bnAb germline precursor B cells. Critical unmet challenges are to determine whether bnAb precursor naïve B cells bind germline-targeting immunogens and occur at sufficient frequency in humans for reliable vaccine responses. Using deep mutational scanning and multitarget optimization, we developed a germline-targeting immunogen (eOD-GT8) for diverse VRC01-class bnAbs. We then used the immunogen to isolate VRC01-class precursor naïve B cells from HIV-uninfected donors. Frequencies of true VRC01-class precursors, their structures, and their eOD-GT8 affinities support this immunogen as a candidate human vaccine prime. These methods could be applied to germline targeting for other classes of HIV bnAbs and for Abs to other pathogens.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom